Skip to main content

Table 4 Summary of relative risk (95% CI excluding one) of adverse events occurring in ≥10% of patients in either of the treatment arms (Chinese safety population)

From: Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

 Relative risk (pazopanib/sunitinib) 
Preferred termPazopanib (N = 109)Sunitinib (N = 100)Ratio95% CIP value
Skin hypopigmentation13 (12)3 (3)3.98(1.167–13.543)0.0270
Hair color changes47 (43)13 (13)3.32(1.912–5.755)< 0.001
Diarrhea57 (52)37 (37)1.41(1.034–1.932)0.0309
Blood creatinine increased21 (19)32 (32)0.60(0.373–0.972)0.0362
Neutrophil count decreased25 (23)40 (40)0.57(0.377–0.872)0.0086
Platelet count decreased23 (21)39 (39)0.54(0.349–0.838)0.0059
Eyelid edema16 (15)28 (28)0.52(0.302–0.910)0.0200
Thrombocytopenia20 (18)39 (39)0.47(0.295–0.750)0.0016
White blood cell count decreased17 (16)33 (33)0.47(0.281–0.794)0.0044
Blood lactate dehydrogenase increased9 (8)18 (18)0.46(0.216–0.974)0.0429
Blood thyroid stimulating hormone increased8 (7)19 (19)0.39(0.177–0.843)0.0179
Peripheral edema6 (6)14 (14)0.39(0.157–0.984)0.0440
Hemoglobin decreased13 (12)31 (31)0.38(0.214–0.693)0.0013
Stomatitis4 (4)12 (12)0.31(0.102–0.917)0.0362
Anemia7 (6)25 (25)0.26(0.116–0.568)< 0.001
Nasopharyngitis2 (2)10 (10)0.18(0.041–0.817)0.0244
Facial edema3 (3)17 (17)0.16(0.049–0.536)0.0052
Yellow skin3 (3)22 (22)0.13(0.039–0.405)< 0.001
Xanthochromia1 (< 1)10 (10)0.09(0.012–0.704)0.0203
  1. CI Confidence interval